Medios AG, together with its subsidiaries, engages in the wholesale of specialty pharmaceutical drugs in Germany. It operates through Pharmaceutical Supply and Patient-Specific Therapies segments. The Pharmaceutical Supply segment offers products on oncology, neurology, autoimmunology, ophthalmology, infectiology, and hemophilia diseases. The Patient-Specific Therapies segment manufactures medications for patients on behalf of pharmacies; and patient-specific therapies for dispensing individually dosed tablets. The company was founded in 2016 and is based in Berlin, Germany.
P/E ratio for Medios AG (ILM1.DE)
P/E ratio as of 2023: 20.07
According to Medios AG's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 20.07. At the end of 2022 the company had a P/E ratio of 22.69.
P/E ratio history for Medios AG from 2009 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | 20.07 |
| 2022 | 22.69 |
| 2021 | 105.17 |
| 2020 | 104.59 |
| 2019 | 39.40 |
| 2018 | 44.10 |
| 2017 | 61.63 |
| 2016 | -10.68 |
| 2015 | -1.42 |
| 2014 | -6.87 |
| 2013 | -1.29 |
| 2012 | -1.04 |
| 2011 | 0.00 |
| 2010 | 0.00 |
| 2009 | 0.00 |